AR085800A1 - Vacuna de rinitis equina - Google Patents

Vacuna de rinitis equina

Info

Publication number
AR085800A1
AR085800A1 ARP120100823A ARP120100823A AR085800A1 AR 085800 A1 AR085800 A1 AR 085800A1 AR P120100823 A ARP120100823 A AR P120100823A AR P120100823 A ARP120100823 A AR P120100823A AR 085800 A1 AR085800 A1 AR 085800A1
Authority
AR
Argentina
Prior art keywords
strain
identity
erav
equine
erab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP120100823A
Other languages
English (en)
Inventor
Phillip Wayne Hayes
Kristina J Hennessy
Laurent Viel
Andres Diaz-Mendez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Original Assignee
Boehringer Ingelheim Vetmedica de C V SA
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica de C V SA, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica de C V SA
Publication of AR085800A1 publication Critical patent/AR085800A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Composiciones inmunogénicas contra virus de rinitis equina, en particular virus de rinitis equina A y B y métodos para su uso y su preparación. Las composiciones inmunogénicas, en formas de realización alternativas, también incluyen otros agentes patógenos de equinos.Reivindicación 1: Una composición inmunogénica caracterizada porque comprende una o varias cepas de inactivados o vivos, atenuados el virus de rinitis equina A (ERAV) o virus de rinitis equina B (ERBV), a) en donde la cepa de ERAV o la cepa de ERAB, antes de la inactivación o atenuación, causa una enfermedad respiratoria detectable en al menos el 50% de caballos seronegativos expuestos a la cepa; y/o b) crecidos en cultivo celular a 106 TCID50/mL o más; y/o, c) cuando se usa como una vacuna en equinos en una dosis de 106 TCID50 o más da como resultado una titulación sérica de al menos 1:112; y/o d) en donde dicha cepa de ERAV comprende una secuencia genómica cuyo transcripto inverso tiene más del 95% de identidad con la SEQ ID Nº 2; y/o e) en donde dicho ERAV codifica una poliproteína con una secuencia de aminoácidos con más del 95% de identidad con la SEQ ID Nº 3; y/o f) en donde dicha cepa de ERBV comprende una secuencia genómica cuyo transcripto inverso tiene más del 95% de identidad con el transcripto inverso de la secuencia genómica de la cepa de ERAB que tiene número de acceso ATCC PTA-11829; y/o g) en donde dicha cepa de ERVB codifica una poliproteína con una secuencia de aminoácidos con más del 95% de identidad con la poliproteína codificada por el genoma de la cepa de ERAB que tiene número de acceso ATCC PTA-11829.
ARP120100823A 2011-03-14 2012-03-13 Vacuna de rinitis equina Pending AR085800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US201161510226P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
AR085800A1 true AR085800A1 (es) 2013-10-30

Family

ID=45876924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100823A Pending AR085800A1 (es) 2011-03-14 2012-03-13 Vacuna de rinitis equina

Country Status (12)

Country Link
US (1) US9187730B2 (es)
EP (2) EP2772266B1 (es)
AR (1) AR085800A1 (es)
AU (2) AU2012229192B2 (es)
BR (2) BR122019023542B1 (es)
CA (2) CA3018230A1 (es)
ES (2) ES2748555T3 (es)
MA (1) MA35303B1 (es)
MX (1) MX350718B (es)
NZ (1) NZ614147A (es)
TW (1) TW201300537A (es)
WO (1) WO2012125525A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2772266B1 (en) 2011-03-14 2019-07-31 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine
CA2967532A1 (en) 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
CA2438692C (en) 2001-02-28 2010-04-27 Akzo Nobel Nv Injectable water-in-oil emulsions
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
WO2003061555A2 (en) 2001-07-27 2003-07-31 Wyeth West nile vaccine
JP5164305B2 (ja) 2001-10-19 2013-03-21 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 動物におけるフラビウイルス感染を予防および治療する方法
DE60330708D1 (de) 2002-11-15 2010-02-04 Sanofi Pasteur Biologics Co Impfstoff gegen das west-nile-virus
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US7585621B2 (en) 2003-09-09 2009-09-08 Idexx Laboratories, Inc. Detection of West Nile virus infection and vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
US7862829B2 (en) 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1645283A1 (en) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
BRPI0611581B1 (pt) 2005-06-24 2021-08-03 Intervet International B.V. Flavivírus quimérico inativado, composição imunogênica, e, vacina
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
CN101309701A (zh) 2005-10-07 2008-11-19 辉瑞产品公司 治疗犬流感的疫苗和方法
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
AU2006310555B2 (en) 2005-11-01 2011-08-04 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
WO2010025469A1 (en) 2008-08-29 2010-03-04 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
EP2772266B1 (en) 2011-03-14 2019-07-31 Boehringer Ingelheim Animal Health USA Inc. Equine Rhinitis vaccine

Also Published As

Publication number Publication date
NZ708320A (en) 2016-08-26
EP2686012B1 (en) 2020-12-02
BR112013023354A2 (pt) 2016-12-06
ES2748555T3 (es) 2020-03-17
BR122019023542B1 (pt) 2022-02-15
AU2012229192A1 (en) 2013-08-29
AU2012229192B2 (en) 2017-04-20
CA3018230A1 (en) 2012-09-20
US9187730B2 (en) 2015-11-17
EP2686012A2 (en) 2014-01-22
CA2829226A1 (en) 2012-09-20
EP2772266B1 (en) 2019-07-31
TW201300537A (zh) 2013-01-01
AU2017201526A1 (en) 2017-03-30
AU2017201526B2 (en) 2019-07-18
MA35303B1 (fr) 2014-08-01
EP2772266A1 (en) 2014-09-03
NZ614147A (en) 2015-08-28
AU2017201526C1 (en) 2019-10-24
CA2829226C (en) 2023-01-03
BR112013023354B1 (pt) 2022-02-15
MX2013010125A (es) 2013-10-07
WO2012125525A2 (en) 2012-09-20
ES2842595T3 (es) 2021-07-14
US20120237543A1 (en) 2012-09-20
WO2012125525A3 (en) 2013-02-28
MX350718B (es) 2017-09-14

Similar Documents

Publication Publication Date Title
Sheahan et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus
ME01156B (me) Postupci i kompozicije za imunizaciju svinja protiv svinjskog cirkovirusa
CL2016000240A1 (es) Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal.
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
Chen et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with alum induces protective immunity and reduces immune enhancement
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
AR065076A1 (es) Vacuna contra el papilomavirus
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
UY32274A (es) Pestivirus quimericos
AR106026A1 (es) Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
WO2017156511A8 (en) Live attenuated zika virus vaccine
PE20140871A1 (es) COMPOSICIONES Y METODOS DE VACUNA DEL VIRUS TIPO 1b DE DIARREA VIRAL BOVINA
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
EA201390812A1 (ru) Лиофилизированные вирусные составы
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR103427A1 (es) Vacuna contra la fiebre aftosa
AR085800A1 (es) Vacuna de rinitis equina
CO2019013220A2 (es) Virus oncolíticos y método
Swati et al. Isolation and phylogenetic characterization of Canine distemper virus from India
AR081409A1 (es) PARAPOXVIRUS RECOMBINANTE CONTENIENDO ADN HETERoLOGO DERIVADO DE UN VIRUS DE LA RABIA (RV)
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
BR112019008584A2 (pt) vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo

Legal Events

Date Code Title Description
FC Refusal